Package 0615-8569-39

{"route": ["ORAL"], "spl_id": "2f01abe1-4355-4e2f-8d50-99fa12542add", "openfda": {"nui": ["N0000175427", "N0000190114", "N0000185503", "N0000182137", "N0000187061"], "unii": ["A6IEZ5M406"], "rxcui": ["616749"], "spl_set_id": ["96dd12c2-5409-4081-8242-4774741d9822"], "pharm_class_epc": ["Anti-anginal [EPC]"], "pharm_class_moa": ["Cytochrome P450 3A Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Organic Cation Transporter 2 Inhibitors [MoA]"], "manufacturer_name": ["NCS HealthCare of KY, LLC dba Vangard Labs"]}, "finished": true, "packaging": [{"sample": false, "description": "30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK (0615-8569-39)", "package_ndc": "0615-8569-39", "marketing_end_date": "20260331", "marketing_start_date": "20250220"}], "brand_name": "Ranolazine", "product_id": "0615-8569_2f01abe1-4355-4e2f-8d50-99fa12542add", "dosage_form": "TABLET, FILM COATED, EXTENDED RELEASE", "pharm_class": ["Anti-anginal [EPC]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "Organic Cation Transporter 2 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]"], "product_ndc": "0615-8569", "generic_name": "Ranolazine", "labeler_name": "NCS HealthCare of KY, LLC dba Vangard Labs", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Ranolazine", "active_ingredients": [{"name": "RANOLAZINE", "strength": "500 mg/1"}], "application_number": "ANDA212284", "marketing_category": "ANDA", "marketing_end_date": "20260331", "marketing_start_date": "20200401"}